C6-galactose mustard

C6-GLM (C6-galactose mustard) is a galactose-linked nitrogen mustard derivative developed as an alkylating antineoplastic agent. It was designed to reduce the characteristic bone marrow toxicity associated with conventional nitrogen mustards by conjugating the cytotoxic bis(2-chloroethyl)amino group to the carbon-6 position of a galactose sugar molecule. In preclinical studies, C6-GLM demonstrated significant antitumor activity against P388 leukemia and B-16 melanoma in murine models, showing superior or comparable efficacy to nitrogen mustard with significantly less impact on white blood cell counts and bone marrow DNA synthesis. The drug's mechanism of action involves the alkylation of DNA, which leads to interstrand cross-linking and the subsequent inhibition of DNA replication and tumor cell proliferation.

Other names

6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride6-deoxy-6-[bis(2-chloroethyl)amino]-D-galactoseC6-galactose nitrogen mustardC-6-galactose nitrogen mustardC 6-galactose nitrogen mustard